share_log

Roth Capital Reinstates Buy on Rain Oncology, Announces $21 Price Target

Roth Capital Reinstates Buy on Rain Oncology, Announces $21 Price Target

羅斯資本恢復對雨腫瘤學的購買,宣布 21 美元目標價
Benzinga Real-time News ·  2023/01/31 08:34

Roth Capital analyst Kumaraguru Raja reinstates Rain Oncology (NASDAQ:RAIN) with a Buy and announces $21 price target.

羅斯資本分析師庫馬拉古拉賈以買入恢復了雨腫瘤學(NASDAQ:RAIN),並宣布 21 美元的目標價格。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論